Puneet Souda
Stock Analyst at Leerink Partners
(1.59)
# 3,454
Out of 5,090 analysts
218
Total ratings
48.59%
Success rate
-0.74%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $572.77 | +1.26% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $74.97 | +4.04% | 8 | Oct 21, 2025 | |
| GH Guardant Health | Maintains: Outperform | $70 → $75 | $102.02 | -26.49% | 6 | Sep 25, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $9.54 | +67.71% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.57 | +82.65% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $7.63 | +4.85% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $11.90 | -24.37% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $7.09 | +196.19% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $44.61 | -10.33% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $244.55 | -38.66% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $394.81 | -5.02% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $38.65 | -9.44% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $145.49 | -0.34% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $226.25 | +32.60% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $128.96 | +93.86% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $61.68 | +78.34% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $101.06 | -25.79% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $164.98 | +21.23% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.56 | +405.62% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.95 | +207.69% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $32.30 | -7.12% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $48.03 | +81.14% | 13 | May 5, 2022 |
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $572.77
Upside: +1.26%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $74.97
Upside: +4.04%
Guardant Health
Sep 25, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $102.02
Upside: -26.49%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $9.54
Upside: +67.71%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.57
Upside: +82.65%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $7.63
Upside: +4.85%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $11.90
Upside: -24.37%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $7.09
Upside: +196.19%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $44.61
Upside: -10.33%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $244.55
Upside: -38.66%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $394.81
Upside: -5.02%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $38.65
Upside: -9.44%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $145.49
Upside: -0.34%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $226.25
Upside: +32.60%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $128.96
Upside: +93.86%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $61.68
Upside: +78.34%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $101.06
Upside: -25.79%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $164.98
Upside: +21.23%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.56
Upside: +405.62%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.95
Upside: +207.69%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $32.30
Upside: -7.12%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $48.03
Upside: +81.14%